Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

Aurelia H. M. de Vries Schultink 1 · Robert P. Doornbos 2 · Alexander B. H. Bakker 2 · Kees Boi 2 · Mark Throsby 2 · Cecile Geuijen 2 · David Maussang 2 · Jan H. M. Schellens 3,4 · Jos H. Beijnen 1,4 · Alwin D. R. Huitema 1,5

Received: 19 January 2018 / Accepted: 19 March 2018 / Published online: 5 May 2018
© The Author(s) 2018

Summary

Introduction MCLA-128 is a bispecific monoclonal antibody targeting the HER2 and HER3 receptors. Pharmacokinetics (PK) and pharmacodynamics (PD) of MCLA-128 have been evaluated in preclinical studies in cynomolgus monkeys and mice. The aim of this study was to characterize the PK and PD of MCLA-128 and to predict a safe starting dose and efficacious clinical dose for the First-In-Human study. Methods A PK-PD model was developed based on PK data from cynomolgus monkeys and tumor growth data from a mouse JIMT-1 xenograft model. Allometric scaling was used to scale PK parameters between species. Simulations were performed to predict the safe and efficacious clinical dose, based on AUCs, receptor occupancies and PK-PD model simulations. Results MCLA-128 PK in cynomolgus monkeys was described by a two-compartment model with parallel linear and nonlinear clearance. The xenograft tumor growth model consisted of a tumor compartment with a zero-order growth rate and a first-order dying rate, both affected by MCLA-128. Human doses of 10 to 480 mg q3wk were predicted to show a safety margin of >10-fold compared to the cynomolgus monkey AUC at the no-observed-adverse-effect-level (NOAEL). Doses of ≥360 mg resulted in predicted receptor occupancies above 99% (C_max and C_ave). These doses showed anti-tumor efficacy in the PK-PD model. Conclusions This analysis predicts that a flat dose of 10 to 480 mg q3wk is suitable as starting dose for a First-in-Human study with MCLA-128. Flat doses ≥360 mg q3wk are expected to be efficacious in human, based on receptor occupancies and PK-PD model simulations.

Keywords MCLA-128 · Bispecific · Preclinical · Translational · PK-PD modeling

Introduction

MCLA-128 is a full length humanized IgG1 bispecific monoclonal antibody (mAb) with enhanced antibody-dependent cell mediated cytotoxicity (ADCC) targeting the HER2 and HER3 receptor tyrosine kinases. MCLA-128 is developed to overcome HER3-mediated resistance to EGFR and HER2-targeted therapies. Current HER2-targeted therapies are approved for HER2-amplified breast and gastric cancers, either as single agents or in combination with other anti-cancer drugs [1, 2]. However, a proportion of patients treated with these therapies show primary or acquired resistance [3, 4]. A major resistance mechanism is mediated via HER3 activation. Its ligand heregulin drives dimerization of HER3 with HER2, resulting in potent activation of the PI3K/AKT pathway with subsequent enhanced growth and survival of HER2-amplified
tumors. Heregulin stimulation was shown to mediate resistance to trastuzumab and lapatinib therapy [5–7]. Alternatively, HER3 upregulation in HER2-amplified tumors can also result in ligand-independent dimerization of HER3 with HER2 and enhanced cell survival [7]. The simultaneous targeting of HER2 and HER3 by MCLA-128 could overcome this resistance. MCLA-128 is expected to directly inhibit tumor growth by blocking HER2:HER3 signaling and, through the ADCC mechanism, eliminate tumor cells via recruitment of natural killer effector cells to tumor cells coated with MCLA-128.

In vitro results show that MCLA-128 inhibits proliferation of HER2 over-expressing and HER2-low cells stimulated with heregulin. MCLA-128 shows significantly higher potency than lapatinib, trastuzumab alone or to the combination of trastuzumab and pertuzumab [8].

Preclinical in vivo research was conducted in cynomolgus monkeys and in tumor xenograft models in mice to understand the preclinical pharmacokinetics (PK) and pharmacodynamics (PD) of MCLA-128. The aim of this study was to develop a preclinical PK-PD model for MCLA-128 based on (i) PK characteristics of MCLA-128 in cynomolgus monkeys and (ii) the effect of MCLA-128 on tumor growth in mouse xenograft models. The preclinical PK model was used to predict the safe starting dose in humans, to support selection of the First-In-Human dose for the Phase I dose-finding trial, and to identify the clinical doses that reach a sufficient percentage of receptor occupancy. In addition, the full preclinical PK-PD model was used to evaluate the anti-tumor activity of the proposed clinical doses.

**Material and methods**

**Generation of MCLA-128**

MCLA-128 was engineered using proprietary CH3 technology, and is composed of two identical common light chains and two different heavy chains (anti-HER2 and anti-HER3). ADCC-enhancement was achieved by low fucose glycoengineering using the GlymaxX® technology [8].

**Data (1) PK of MCLA-128 in cynomolgus monkeys**

PK data from 28 cynomolgus monkeys was combined from a single dose toxicity study and the first week of a repeated dose toxicity study. In the single dose toxicity study, 14 blood samples per animal were drawn and sampling times ranged from 0 to 1007 h. Each dosing regimen of 10 mg/kg, 30 mg/kg and 100 mg/kg was administered intravenously to one female and one male animal (total \( n = 6 \)). In the repeated dose toxicity study, 22 animals received a weekly dose of MCLA-128 for five weeks; only data from the first week was included in the analysis. A dosing regimen of 10 mg/kg (\( n = 6 \)), 30 mg/kg (\( n = 6 \)) and 100 mg/kg (\( n = 10 \)) was administered with equal distribution between female and male animals. Ten samples per animal were drawn and sampling times ranged from 0 to 168 h. MCLA-128 was quantified in serum using a validated electrochemiluminescence immunoassay (lower limit of quantification (LLOQ): 78 ng/mL). The experiments in cynomolgus monkeys were conducted at Charles River Laboratories Edinburg (preclinical services). All procedures were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986, approved by institutional ethical review committees and conducted under the authority of the Project License.

**Data (2): Antitumor efficacy in xenograft models**

MCLA-128 antitumor activity was evaluated in a human breast carcinoma model using the JIMT-1 cell line. In this experiment, 8 to 12 weeks old female CB.17 SCID mice were injected subcutaneously in the right flank with \( 5 \times 10^6 \) JIMT-1 tumor cells. Treatment started 8 days after tumor cell implantation, with tumor volumes ranging from 108 to 172 mm³. Animals (\( n = 10 \) per group) received weekly intraperitoneal (i.p) injections of either phosphate buffered saline, MCLA-128 at 2.5 mg/kg or MCLA-128 at 25 mg/kg for four weeks (4 doses in total). Mice were euthanized on day 68 or when tumor size reached 800 mm³. Tumors from mice were extracted 24 h after the last dose. Tumor size was determined with a caliper twice weekly and tumor volume was calculated using the following equation: tumor volume (mm³) = (width²·length) · 0.5. Efficacy data were used to develop the PD model.

Mouse xenograft studies were performed by Charles River Discovery Services North Carolina, USA and the experimental protocol was approved by the site’s Institutional Animal Care and Use Committee. The facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

**PK modeling**

The structural PK characteristics of monoclonal antibodies (mAbs) are usually described by a two-compartment model with either linear, nonlinear or parallel linear and nonlinear clearances [9]. Antibodies follow primarily linear clearance through cellular uptake followed by lysosomal degradation, mediated by the neonatal Fc receptor (FcRn). In addition, the Fab region of the antibody can bind to the target receptor, leading to a saturable clearance pathway, known as target mediated drug disposition (TMDD) [10, 11]. The starting point for model development in the current analysis was a two-compartment model for which different combinations of
linear and nonlinear clearance were evaluated. The PK model was directly scaled to a 70 kg human using allometric scaling.

**Tumor growth modeling**

Non-perturbed tumor growth models were evaluated in the untreated mice. Different growth models were evaluated, such as Gompertz growth, zero-order growth (linear) and first-order (exponential) growth [12].

PK sampling was not performed in the xenograft study. Therefore, the previously established PK model developed based on cynomolgus monkey data was allometrically scaled to a 0.02 kg mouse to predict concentration-time profiles and assess their relation to tumor growth in the treated animals [13, 14].

The MCLA-128 anti-tumor effect was modeled to impact either the tumor growth rate (K_G), the tumor dying rate (K_D) or both. Different models to describe these effects were evaluated, such as direct effect models, indirect response models and use of transit and effect compartments, to establish the correct delay in effect, seen in the individual plots describing tumor volume over time. The drug effect was modeled as either a linear effect or an E_max model. Additionally, a tumor growth rate increase over time was considered.

**Statistical model development**

Inclusion of inter individual variability was considered for all structural model parameters as follows:

\[ P_i = P_{pop} \exp(\eta_i) \]

Where \( P_i \) is the individual parameter estimate for individual \( i \), and \( P_{pop} \) is the typical population parameter estimate, and where \( \eta_i \) was assumed to be distributed normally distributed with mean 0 and variance \( \omega^2 \). Residual unexplained variability was described as a proportional and additive error model for the PK model:

\[ C_{obs,ij} = C_{pred,ij}(1 + \varepsilon_p,ij) + \varepsilon_{a,ij} \]

For the PD part of the model residual variability was described by a proportional error model:

\[ C_{obs,ij} = C_{pred,ij}(1 + \varepsilon_p,ij) \]

Where \( C_{obs,ij} \) represents the observed concentration for individual \( i \) and observation \( j \), \( C_{pred,ij} \) represents the individual predicted concentration, \( \varepsilon_p,ij \) the proportional error and \( \varepsilon_{a,ij} \) the additive error, both distributed following N (0,\( \sigma^2 \)).

For PK data, the first data point below the LLOQ (78 ng/mL) was fixed to LLOQ/2 and a fixed additive error component of LLOQ/2 was included in the model to account for uncertainty in these observations [15].

**Model evaluation**

Models were evaluated based on general goodness-of-fit (GOF) plots, plausibility, stability and precision of parameter estimates and change in objection function value (OFV) where a \( p < 0.01 \) was considered significant, meaning that a OFV drop of >6.63 (degree of freedom = 1) was considered as a significant improvement.

**Software**

Data management, graphical evaluation and simulations were performed using R (version 3.0.1) [16]. Nonlinear mixed-effects modeling was performed using NONMEM (version 7.3.0, ICON Development Solutions, Ellicott City, MD, USA) and Perl-speaks-NONMEM (version 4.4.8) [17, 18]. Pirana (version 2.9.2) was used as graphical user interface [19]. All models were estimated using First Order Conditional Estimation method with \( \eta-\varepsilon \) interaction (FOCE-I).

**Determination of the safe starting dose and clinical efficacious dose**

A safe starting dose for the First-In-Human study of MCLA-128 was identified by calculation of safety margins based on the simulated exposure in humans at different dose levels. Subsequently, a clinical target exposure and dose was determined by calculation of receptor occupancies for different dose levels, based on the simulated exposures in human and the estimated \( K_m \) value. Doses with a receptor occupancy above 99%, based on the maximum and average MCLA-128 concentration in the first cycle, were expected to have a clinical effect. In addition, a simulation with the tumor growth model was performed in mice, to evaluate the potential human anti-tumor efficacy of the proposed clinical dose regimens.

First, the safety margins were calculated for different simulated dose levels. The safety margins were based on the no-observed-adverse-effect-level (NOAEL) of MCLA-128 in monkeys included in the multiple dose toxicity study, which was determined at 100 mg/kg. The mean AUC0-inf of 193 g-hr/L was calculated using the PK data of the monkeys included in the single dose toxicity study that received 100 mg/kg, to assure that the exposure to MCLA-128 was not compromised by possible generation of anti-drug antibodies. The safety margin was calculated by dividing the 193 g-hr/L AUC0-inf by the predicted model-based AUC0-inf. The AUCs were computed using a non-compartmental analysis of both the observed and simulated data. Second, the receptor occupancies based on the maximal, trough and average concentrations (Cmax, Ctrough and Cave, respectively) were calculated, using the same simulated exposure data as used for obtaining the safety uncertainty in these observations [15].
The receptor occupancies were calculated based on the estimated $K_m$ value, using the following equation:

$$\%RO = 100 \times \frac{C_{\text{max or trough or average}}}{K_m + C_{\text{max or trough or average}}}$$

Lastly, to evaluate the potential human anti-tumor efficacy the proposed clinical dose regimens for MCLA-128 were evaluated with the preclinical PK-PD model in mice. Tumor stasis at day 21 was evaluated after applying a regimen of a weekly dose for three weeks. The dose input was chosen so that the total exposure (AUC) of the three doses, mimicked the exposure of proposed clinical doses administered once in a 21-day cycle.

**Results**

**PK model**

A two-compartment model with parallel linear and nonlinear clearances from the central compartment described the data best. The nonlinear clearance was described using Michaelis-Menten kinetics. The final model structure was defined by the following differential equations:

$$\frac{d(A_1)}{dt} = -\frac{CL}{V_1} \cdot A_1 - \frac{V_{\text{max}}}{K_m + C_1} \cdot \frac{Q}{V_1} \cdot A_1 + \frac{Q}{V_2} \cdot A_2$$

$$\frac{d(A_2)}{dt} = \frac{Q}{V_1} \cdot A_1 - \frac{Q}{V_2} \cdot A_2$$

Where $CL$ represents the linear clearance, $Q$ the intercompartmental clearance, $V_1$ the volume of distribution in the central compartment and $V_2$ the volume of distribution in the effect compartment, $A_1$ the amount of drug in the central compartment, $V_{\text{max}}$ the maximum elimination rate, $C_1$ the drug concentration in the central compartment, $K_m$ the drug concentration at which half the drug-targets are occupied and $A_2$ the amount in the peripheral compartment. Scaling of the model to a 70 kg human or 0.02 kg mouse was performed using the following equations, respectively:

$$P_{\text{monkey, pop}} = \theta_{\text{human, pop}} \cdot \left( \frac{WT}{70} \right)^{\text{factor}}$$

$$P_{\text{mouse, pop}} = \theta_{\text{human, pop}} \cdot \left( \frac{0.02}{70} \right)^{\text{factor}}$$

On $CL$, $Q$, and $V_{\text{max}}$ a factor of 0.75 was used and on $V_1$ and $V_2$ a factor of 1 was used. MCLA-128 is fully cross-reactive with cynomolgus monkey HER2 and HER3 receptors and mice were implanted with human HER2 and HER3 expressing tumors. Therefore, $K_m$ was not scaled and fixed to the parameter estimate in cynomolgus monkeys (0.219 mg/L) for both human and mice [20, 21]. Parameter estimates for a 70 kg human and the calculated scaled parameters for a 0.02 kg mouse are depicted in Table 1. The visual predictive checks (VPCs) demonstrate that the model accurately describes the observed PK data in cynomolgus monkeys for each dose-group (Fig. 1).

**PK-PD model**

The preclinical PK-PD model was based on the scaled PK model from cynomolgus monkeys to mice and the xenograft experiments conducted in mice. First, the non-perturbed tumor growth in the vehicle-treated mice was modelled. This was best described by a zero-order growth rate ($K_G$). The MCLA-128 anti-tumor effect in this experiment was modeled to target the proliferation and dying rate ($K_G$ and $K_D$) of the tumor. The effect on $K_G$ was described by an indirect response model, where the in-rate ($K_{\text{int}}$) in the indirect effect compartment was affected by the predicted MCLA-128 concentration using an inhibitive $E_{\text{max}}$ equation. The effect of the predicted MCLA-128 concentrations on $K_D$ was modeled directly with an $E_{\text{max}}$ model. An indirect response model and effect compartment model were evaluated to investigate a delay of the effect on $K_D$, but this could not be identified. Addition of an increasing tumor growth rate over time (modelled by inclusion of the $\lambda$ term) led to a significant increase of model fit and was implemented in the final model. The structural model is depicted in Fig. 2 and the estimated PD model parameters are depicted in Table 2. Goodness of fit plots and a plot demonstrating observed tumor volume versus predicted population mean, demonstrated adequate fit of the model (Figs. 3 and 4).

**Safe starting dose and clinical efficacious dose**

The safety margins and percentages receptor occupancies at predicted maximum, trough and average concentrations were calculated for the anticipated clinical doses. Results are depicted in Table 3. Clinical doses ranging from 10 to 480 mg flat dose MCLA-128 showed a safety margin $>10$-fold and doses $\geq 360$ mg had an expected receptor occupancy higher than 99% for both $C_{\text{max}}$ and $C_{\text{ave}}$. In addition, a sensitivity analysis for the $K_m$ was conducted for $K_m$ values ranging from 0.0219 mg/L to 2.19 mg/L, since this parameter showed a high relative standard error (RSE) of 74% value in the monkey estimation. The sensitivity analysis showed permanent adequate receptor occupancies for varying $K_m$ values and values of higher than 99% for doses starting from 160 mg ($K_m$ of 0.0219 mg/L) and 750 mg ($K_m$ 2.19 mg/L). Subsequently, the tumor volumes over time in 0.02 kg mice were simulated with the established preclinical PK-PD model for dose levels of
9.5 mg/kg, 20 mg/kg and 24 mg/kg given once every week (q1wk) for 3 weeks (Fig. 5). These dose levels had AUCs corresponding to the 360 mg, 750 mg and 900 mg flat dose of MCLA-128 given q3wk in the First-In-Human study, and demonstrated profound tumor stasis at day 21.

Discussion

In this analysis, the preclinical PK characteristics of MCLA-128 were quantified in cynomolgus monkeys and subsequently predicted for humans. The PK profiles were well described by a two-compartment model with parallel linear and nonlinear clearance pathways. Predicted parameters were in accordance with previously published PK characteristics of different therapeutic mAbs in human, with a median (range) of $V_1$ and $V_2$ of 3.1 L (2.4–5.5) and 2.8 L (1.3–6.8), respectively, and for linear clearance ($CL_L$) 0.013 L/h (0.003–0.223) [9]. Estimates for $V_{max}$ and $K_m$ varied widely among the different IgG mAbs, but the Michaelis Menten estimates for MCLA-128 were within this wide range [9]. Cynomolgus monkeys are considered to be the most relevant species to predict PK of monoclonal antibodies in human [22]. In addition, healthy cynomolgus monkeys express HER2 and HER3 receptors with binding epitopes for MCLA-128 that are conserved.
between human and cynomolgus monkeys. This is a require-
ment to determine the nonlinear (target mediated) clearance
pathway. Moreover, the design of MCLA-128 using the CH3
engineering and the low fucose glycoengineering technolo-
gies did not alter the IgG PK characteristics of the compound,
since PK parameters were in the range of previously published
parameters of other therapeutic IgG mAbs.

Subsequently, the established PK model was used to pre-
predict safety in humans. Dose levels of 10 to 480 mg flat dose of
MCLA-128 given q3wk have predicted AUCs that are at least
10-fold lower than the NOAEL corresponding AUC in mon-
keys. Doses of 10 to 480 mg were, therefore, considered
suitable as a First-In-Human starting dose. However, follow-
ing the CHMP guideline on identifying and mitigating risk for
such studies [23], other non-clinical safety pharmacology and
toxicology data should also be taken into account to determine
the optimal starting dose for the Phase I dose-escalation trial,
including the identification of the factors of risk. Concerns
may be derived from particular knowledge or lack thereof
regarding the mode of action, the nature of the target, and/or
the relevance of animal models. Obtaining the exposures in
humans using a PK modeling and simulation approach is pre-
ferred over traditional calculation of the human equivalent
dose, since (non-linear) pharmacokinetic characteristics are

### Table 2
Population parameter estimates for the preclinical PK/PD model: the effect of MCLA-128 on tumor growth in JIMT-1 xenograft models

| Parameter                                                                 | Units   | Parameter estimates | RSE (%) | Shrinkage (%) |
|--------------------------------------------------------------------------|---------|---------------------|---------|---------------|
| Population PD parameters in mice                                         |         |                     |         |               |
| Tumor baseline value (Base)                                              | mm³     | 177                 | 6.7     | –             |
| Zero order tumor growth rate (K_G)                                       | hr⁻¹    | 0.338               | 22.2    | –             |
| First order tumor dying rate (K_D)                                       | mm³/h   | 0.004               | 15.9    | –             |
| Production and loss of drug effect on K_G (K_i0)                         | hr⁻¹    | 0.143               | 18.3    | –             |
| MCLA-128 concentration with 50% of maximum effect on K_i0 (EC50)         | mg/L    | 2.60                | 47.7    | –             |
| MCLA-128 concentration with 50% of maximum effect on K_D (EC50_KD)       | μg/L    | 0.0102              | 25.1    | –             |
| Progression factor                                                      | week⁻¹  | 0.172               | 23      | –             |
| Between-subject variability (%)                                         |         |                     |         |               |
| Baseline                                                                | CV      | 20.6                | 16.8    |               |
| K_G                                                                     | CV      | 55.1                | 1.10    |               |
| K_D                                                                     | CV      | 35.5                | 24.8    |               |
| Residual variability                                                    |         |                     |         |               |
| Proportional residual error tumor compartment                           | CV      | 25.6                | 7.4     | 5.9           |

Population PK parameters were scaled to mice to drive the tumor growth model, parameters reported in Table 1

RSE, relative standard error; CV, coefficient of variation; SD, standard deviation
taken into account [24, 25]. In addition, antibodies are suitable compounds for this approach, since no metabolites are formed and no enzymatic metabolism is present, which might trouble the prediction of exposure from animal to human [9, 22].

The PK model was then used to determine the pharmacological active doses based on receptor occupancies. Doses $\geq 360 \text{ mg flat dose of MCLA-128 given q3wk}$ are expected to reach a receptor occupancy superior to 99% at $C_{\text{max}}$ and $C_{\text{avg}}$, and at $C_{\text{trough}}$ of 24%. However, the receptor occupancies are calculated using the model estimated $K_m$ value based on healthy cynomolgus monkeys. These cynomolgus monkeys did not bear HER2/HER3 expressing tumors, but only endogenously expressed HER3 and HER2 epitopes. It is expected that tumor-bearing patients demonstrate higher expression of HER2 and HER3 receptors. Therefore, the clinical model estimate for the $V_{\text{max}}$ and $K_m$ could be different. The sensitivity analysis demonstrated that for a 10-fold increase in

**Fig. 3** Goodness of fit plots tumor growth model, CWRES = conditional weighted residuals

**Fig. 4** Individual tumor volume over time curves for each dose group (vehicle, 2.5 mg/kg and 25 mg/kg). Blue dots and lines = observed tumor volumes, red line = population prediction

• Springer
the $K_m$ value, a 750 mg flat dose MCLA-128 would attain a receptor occupancy of 99% at $C_{\text{max}}$. In addition, for trastuzumab, a $K_m$ value of 3.7 mg/L has been identified in patients with HER2-amplified advanced gastric or gastroesophageal junction cancer [26]. This $K_m$ is in the same order of magnitude as the $K_m$ of MCLA-128 used in the sensitivity analysis (2.19 mg/L). Moreover, in breast cancer, only linear PK models for trastuzumab have been identified potentially indicating that all target is saturated and, that the target mediated clearance of trastuzumab is of minor importance in breast cancer at therapeutic dose levels [27].

Finally, the proposed effective doses in human were evaluated using the preclinical PK-PD model. The final tumor growth (PD) model included an effect on the tumor growth rate and on the tumor dying rate. The low EC$_{50}$ value for the effect on $K_D$ (EC$_{50,KD}$) suggests that the anti-tumor activity is present during almost the complete time course between administrations in mice for doses of 2.5 mg/kg and higher. The JIMT-1 cell line has higher HER2 expression than HER3 expression and is reported to overexpress the HER3 ligand heregulin [28, 29]. The JIMT-1 cell line is resistant to HER2 targeted therapies and partially dependent on autologous heregulin for growth which can be effectively blocked in vitro by MCLA-128 [28]. The JIMT-1 cell line was therefore considered suitable for determining the direct effect of MCLA-128 on tumor growth in a xenograft setting. However, this approach may underpredict the true anti-tumor efficacy of MCLA-128 due to the inherent limitations of the xenograft models: immunodeficient mice were used in the JIMT-1 xenograft model and therefore the ADCC-related mechanism of action could not be evaluated. As a result, the low EC$_{50,KD}$ is expected to represent the natural dying rate of the tumor resulting from a decrease in tumor growth rate. On the other hand, the exposure of MCLA-128 in mice was predicted using an allometrically scaled PK model, the true exposure in mice is expected to be higher, since humanized mAbs have a high affinity for mouse and rat FcRn, resulting in a decrease in linear clearance, subsequently resulting in higher concentrations [30]. Therefore, it is expected that the EC$_{50}$ parameters for anti-tumor activity are higher than estimated in the preclinical PK/PD model. It is unclear how these two findings are balanced, hence how they affect the preclinical predictions of tumor growth. However, we expect that the true anti-tumor efficacy is stronger than simulated, since lack of the ADCC effect is expected to have a stronger impact on predictions than an increase in the EC$_{50}$ parameter. Nevertheless, MCLA-128 demonstrated a profound anti-tumor activity in mice.

Receptor occupancies based on $C_{\text{max}}$ and $C_{\text{ave}}$ were expected to be >99% starting as of 360 mg MCLA-128.

| Flat dose (mg) | AUC (g·hr/L) | Safety Margin | $C_{\text{max}}$ %RO | $C_{\text{ave}}$ %RO | $C_{\text{trough}}$ %RO |
|---------------|-------------|---------------|-----------------|------------------|----------------|
| 10            | 0.031       | 6226          | 93.5            | 22.6             | 0.021          |
| 20            | 0.10        | 1930          | 96.6            | 48.8             | 0.074          |
| 40            | 0.33        | 585           | 98.3            | 75.1             | 0.253          |
| 80            | 1.00        | 193           | 99.1            | 90.2             | 0.874          |
| 160           | 2.97        | 65            | 99.6            | 96.4             | 3.29           |
| 240           | 5.57        | 35            | 99.7            | 98.1             | 8.12           |
| 360           | 10.4        | 19            | 99.8            | 99.0             | 23.8           |
| 480           | 16.0        | 12            | 99.9            | 99.3             | 75.7           |
| 600           | 22.4        | 9             | 99.9            | 99.5             | 96.5           |
| 750           | 31.4        | 6             | 99.9            | 99.6             | 98.4           |
| 900           | 41.1        | 5             | 99.9            | 99.7             | 99.0           |
| 1000          | 47.9        | 4             | 99.9            | 99.7             | 99.2           |
| 1200          | 62.0        | 3             | 99.9            | 99.8             | 99.3           |

$C_{\text{max}}$, maximum concentration; $C_{\text{ave}}$, average concentration; RO, receptor occupancy; $\%$RO = 100 · $C_{\text{max}}$ or trough or average / ($K_m + C_{\text{max}}$ or trough or average)
given q3wk and receptor occupancies based on $C_{\text{trough}}$ at the end of a 3-week dosing interval were >99% as of 900 mg (Table 3). Since the anti-tumor effects of MCLA-128 are mediated via receptor binding, it is expected that a further increase in dose will not lead to a significant increase in effect, for doses reaching receptor occupancies >99%. Likewise, both drug effects in the PK-PD model were described by an $E_{\text{max}}$ model, confirming an asymptotic approach of the maximum effect. However, the tumor growth model was not able to capture a plateau in effect starting from approximately 360 mg or 900 mg q3wk, because data about receptor and receptor-drug complex concentrations was lacking.

In general, in this analysis all available relevant PK and PD data before start of the First-in-Human trial were combined in a comprehensive modeling framework to fully evaluate the safe starting dose and predicted efficacious dose range. This framework can be applied similarly for the evaluation of other monoclonal antibodies.

**Conclusion**

A preclinical predictive PK-PD model describing the relation between MCLA-128 exposure and tumor volume over time was developed and demonstrated the anti-tumor efficacy of MCLA-128. The calculation of the safety margins demonstrated that flat doses of 10 to 480 mg MCLA-128 given q3wk are expected to be safe as starting dose for a First-In-Human study with MCLA-128 based on the NOAEL exposure in cynomolgus monkeys. However, other non-clinical safety pharmacology and toxicology data should also be taken into consideration to determine the optimal starting dose for the Phase I dose escalation trial, including the identification of the factors of risk. The simulations and the estimations of receptor occupancy for different dose levels showed that flat doses $\geq$360 mg of MCLA-128 given q3wk are likely to be efficacious in human.

**Funding**  This research was funded by Merus N.V.

**Compliance with ethical standards**

**Conflict of interest**  Robert Doornbos, Alexander Bakker, Kees Bo, Mark Throsby, Cecile GeuIJen and David Maussang are employees of Merus N.V. Aurelia de Vries Schultink, Jan Schellens, Jos Beijnen, and Alwin Huijtema declare that they have no conflict of interest.

**Ethical approval**  This article does not contain any studies with human participants performed by any of the authors. The experiments in cynomolgus monkeys were conducted at Charles River Laboratories Edinburg (preclinical services). All procedures were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986, approved by institutional ethical review committees and conducted under the authority of the Project License. Mouse xenograft studies were performed by Charles River Discovery Services North Carolina, USA and the experimental protocol was approved by the site’s Institutional Animal Care and Use Committee. The facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

**Open Access**  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Arteaga CL, SlIwkowski MX, Osborne CK et al (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32
2. Baselga J, Cortes J, Kim S et al (2012) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 366:109–119
3. Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to Trastuzumab in breast Cancer resistance to Trastuzumab in breast Cancer. Clin Cancer Res 15:7479–7491
4. Wilson TR, Fridlyand J, Yan Y et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505–509
5. Sergina NV, Rausch M, Wang D et al (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437–441
6. Garrett JT, Olivares MG, Rinhardt C et al (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021–5026
7. GeuIJen C, Rovers E, Nijhuis R, Visser T (2014) Preclinical activity of MCLA-128, an ADC enhanced bispecific IgG1 antibody targeting the HER2:HER3 heterodimer. J Clin Oncol 32:(suppl; abstr 560)
8. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633–659
9. Dostalek M, Gardner I, Gurbaxani BM et al (2013) Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 52:83–124
10. Gribinski L, Gribinsky E (2009) Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn 36:341–351
11. Ribba B, Holford NH, Magni P et al (2014) A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT pharmacometrics Syst Pharmacol 3:e113
12. Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028–1040
13. Mordenti J, Chen SA, Moore JA et al (1991) Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351–1359
14. Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481–504
16. Team RC, Computing R foundation for S R: A language and Environment for Statistical Computing
17. Beal S, Boeckman A, Sheiner L (1988) NONMEM user guides. San Fransisco, CA
18. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Prog Biomed 75:85–94
19. Keizer RJ, Karlsson MO, Hooker A (2013) Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT pharmacometrics Syst Pharmacol 2:e50
20. Singh AP, Krzyzanski W, Martin SW et al (2015) Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J 17:389–399
21. Dong JQ, Salinger DH, Endres CJ et al (2011) Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50:131–142
22. Deng R, Iyer S, Theil F-P et al (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3:61–66
23. Committee for medicinal products for human use E (2007) Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products
24. Mahmood I, Green MD, Fisher JE (2003) Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692
25. Reigner BG, Blesch K (2002) Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol 57:835–845
26. Cosson VF, Ng VW, Lehle M, Lum BL (2014) Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 73:737–747
27. Bruno R, Washington CB, Lu J-F et al (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361–369
28. Tanner M, Kapanen AI, Junttila T et al (2004) Characterization of a novel cell line established from a patient with Herceptin-resistant. Breast Cancer 3:1585–1592
29. Köninki K, Barok M, Tanner M et al (2010) Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294:211–219
30. Ober RJ (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551–1559